Colorectal cancer is an increasingly important cause of morbidity and mortality, whose 15 incidence is associated with dietary and lifestyle factors, particularly inversely so with the 16 consumption of cruciferous vegetables. These vegetables contain glucosinolates, from the 17 breakdown of which are derived isothiocyanates, such as sulforaphane. Sulforaphane is well-18 characterised for wide-ranging tumour-suppressive and chemoprotective activities in vitro, 19 yet deeper elucidation of its biological interactions would aid in better realising its potential 20 in chemoprevention and/or chemotherapy. There is evidence to suggest that sulforaphane 21 modulates microRNA expression in the colon, thus implying the potential for microRNA 22 modulation to play a role in the anti-cancer effects of sulforaphane. Therefore, the effects of 23 sulforaphane on microRNA expression profiles in the colonic adenocarcinoma Caco-2 and 24 non-cancerous colonic CCD-841 cell lines were investigated by small RNA cloning and deep 25 sequencing, followed by Northern Blot validation experiments. Sulforaphane upregulated let-26 7f-5p and let-7g-5p expression at 24 h in Caco-2 cells, but not in CCD-841. Such treatment 27 also downregulated miR-29b-3p in Caco-2. Dual luciferase assays with a let-7f-5p mimic and 28 inhibitor confirmed the binding of the miRNA to predicted binding sites in the mRNA 29 transcript 3'-UTRs of cell division cycle 25A (CDC25A), high-mobility group AT-hook-2 30 (HMGA2) and MYC. Therefore, we hypothesize that let-7f-5p translationally represses 31 CDC25A, HMGA2 and MYC, thereby playing a role in the tumour-suppressive effects of 32 sulforaphane. The apparent selectivity of let-7f-5p induction towards tumour cells would be 33 therapeutically desirable if applicable in vivo. MiR-29b-3p is predicted to target a number of 34 tumour-suppressing genes, further investigation of which could be informative regarding the 35 potential of sulforaphane to suppress tumour progression. 36 37
Introduction 38
Colorectal cancer is an increasingly major cause of global morbidity and mortality, the latter 39 of which increased by 46% between 1990 and 2010 (1) . Its global incidence was 1.4 million 40 in 2012 (2), making it the third most commonly diagnosed type of cancer (3). It originates 41 from the oncogenic transformation of epithelial cells lining the colon or rectum, which are 42 particularly susceptible to the oxidative, mutagenic and/or inflammatory effects of ingested 43 compounds or products of the gut microbiota. Therefore, it is unsurprising that its incidence 44 has been repeatedly linked to lifestyle and dietary factors, and observed to rise with the 45 adoption of 'Western' dietary habits in a given country (4). Preventative strategies and the 46 screening of asymptomatic individuals for early-stage colorectal cancer are vital, because 47 noticeable symptoms tend not to arise until the cancer has progressed to an advanced and 48 often terminal stage (5). 49
Colorectal cancer risk is particularly inversely correlated with cruciferous vegetable 50 consumption (6), which is likely to be attributable to the derivation of isothiocyanates (ITCs) 51 from the glucosinolates: a group of compounds particular to this group of vegetables that 52 includes broccoli, Brussel sprouts, cabbage and bok choy. Plant cell rupture (e.g. by cooking 53 and/or chewing) enables myrosinase enzymes to hydrolyse the glucosinolates to form several 54 types of product, including ITCs. Broccoli is high in a particular glucosinolate, 55 glucoraphanin, from which is derived a specific ITC known as sulforaphane (SFN). SFN, 56 amongst other ITCs, is a well-established inducer of the nuclear factor (erythroid-derived 2)-57 like 2 (Nrf2) transcription factor, which upregulates the transcription of various antioxidant 58 genes whose promoters contain the antioxidant response element. These help to protect 59 against potentially oncogenic, oxidation-induced, mutagenesis, such as by inhibiting 2-60 amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced DNA damage (7) . It is also 61 widely reported to directly suppress oncogenic characteristics of tumour cell lines, such as 62 cell migration, invasion and proliferation, and to promote cell cycle arrest and apoptosis in 63 such (8) . 64
Moreover, SFN is a hormetic agent, in that the medium-term consequences of low-to-65 moderate exposure -i.e. that reasonably achievable in humans via vegetable consumption -66 tend to be cytoprotective, whereas much higher-dose exposure can be cytotoxic via the 67 induction of oxidative stress and DNA damage (9). This is because SFN acts acutely as a pro-68 oxidant via several mechanisms, including the depletion of cellular glutathione (10) and the 69 disruption of the mitochondrial respiratory chain (11). Low-to-moderate SFN exposure can 70 trigger an Nrf2-mediated anti-oxidative cellular response whose reductive effects outweigh 71 those of the initial pro-oxidant effect in the medium term. On the other hand, the pro-oxidant 72 effects of high-dose exposure may be such as to induce significant oxidative damage to 73 macromolecules and thus result in cytotoxicity rather than cytoprotection. The latter form of 74 activity is obviously undesirable if occurring in healthy cells, but inevitably contributes to the 75 tumour-suppressive effects of SFN observed in tumour cell lines, as described above. 76
Conversely, while the cytoprotective capacity of low-to-moderate dose SFN is desirable in 77 normal cells and helps to protect them against oncogenic transformation, such cytoprotection 78 of tumour cells is undesirable as it may increase their resistance to cytotoxicity-dependent 79 forms of anti-cancer therapy. This has led to speculation that low-to-moderate doses of SFN, 80 whether dietary or supplemental, might even be detrimental to patients undergoing treatment 81 for advanced cancers. However, the 'cytotoxic threshold' of SFN with respect to dose 82 inevitably varies according to cell type, due to variations in basal levels of reactive oxygen 83 species and cell signalling. Notably, a number of studies have indicated tumour cell lines to 84 be more sensitive than their non-cancerous counterparts to SFN-induced cytotoxicity (i.e. to 85 have a lower 'cytotoxic threshold') (12), which opens up the possibility of using SFN at 86 intermediate doses that are simultaneously cytotoxic towards tumour cells yet cytoprotective 87 towards surrounding non-cancerous cells. 88
Clearly, the bioactivity of SFN is highly complex and far from fully understood. Further 89 understanding of SFN's biological interactions is crucial in order to further investigate its 90 potential chemopreventative and/or chemotherapeutic uses. There is evidence to suggest that 91 SFN is able to modulate the expression of miRNAs in several colonic cell lines, from a study 92 by Slaby et al. (13) . Given that miRNAs are well-established as major players in human 93 development and disease progression via their post-transcriptional regulation of gene 94 expression, it is highly probable that SFN's anti-cancer effects are partly attributable to the 95 modulation of miRNA expression. Therefore, a study to investigate the modulation of 96 miRNA expression by SFN in a colonic adenocarcinoma cell line, Caco-2, and a non-97 cancerous colonic cell line, CCD-841, was carried out by first performing a wide-scale assay 98 of SFN-mediated miRNA modulation by small RNA (sRNA) library cloning and deep 99 sequencing, and then verifying the SFN-mediated modulation of specific miRNAs by 100 individual assays. Subsequently, the ability of modulated miRNAs to bind to several 101 computationally-predicted oncogenic mRNA targets was verified in vitro. The insight into the 102 potential bioactivity of SFN provided by the findings of the study with respect to colorectal 103 carcinogenesis could lead to new avenues of research regarding the potential applications of Caco-2 cells were split before exceeding 80% confluence, to avoid their differentiation. 132
Caco-2 cells were tested in the laboratory and found to be mycoplasma free. CCD-841 cells 133
were not tested for mycoplasma in the laboratory. 
RNA Extraction 149
For sRNA library construction, total RNA was extracted using TRI Reagent, according to the 150 manufacturer's instructions (with minor modifications to the protocol). Briefly, cells were 151 lysed in TRI Reagent by directly adding reagent onto attached cells for ≥ 1 min following the 152 removal of culture medium. Lysates were incubated for 5 min at room temperature, then 153 200µL chloroform was mixed per 1mL lysate. Mixtures were incubated at room temperature 154 for 10 min after vigorous shaking, then centrifuged at 16 000 g for 15 min at 4°C. The 155 resulting aqueous, uppermost phases were retained, from which RNA was then recovered by 156 isopropanol precipitation (≥5 h at -20°C) and then centrifugation at ≥ 16 000 g for 30 min. 157
Pellets were recovered, washed in 75% ethanol, dried, and then resuspended in nuclease-free 158
For Northern Blot experiments, either total RNA was extracted in the same manner as that 160 Table S1 for a summary of raw and accepted read numbers per library). Next, 182 the read abundances were normalized by the reads per million (RPM) (19), sRNA-adapted 183 quantile normalization (20) and subsampling (21) methods. The most appropriate 184 normalization method for this dataset was determined to be RPM, conducted on a scaling 185 total of 13 000 000: the median total value. The differential expression analysis was done on 186 the median expression levels of the biological replicates as pairwise comparisons, using an 187 offset fold-change approach (offset=20) (22). All miRNAs with a fold-change The data corresponding to this study are publicly available in the Gene Expression Omnibus 191 (GEO) (23) under accession number GSE89363 (samples GSM2367444 to GSM2367459). 192
For library size class distributions, see Supplementary Figure S1 . For complexity 193 distributions, see Supplementary Figure S2 . For the read annotation analysis and 194 determination of differential expression, see Supplementary Tables S2, S3 and S4. 195 Northern Blotting Phosphorimaging plates were exposed to the radioactively-labelled membranes for 214 appropriate periods of time (typically 6-24 h), and then signals were evaluated using a phosphorimaging scanner. RNA band intensities were densitometrically analyzed using the 216 ImageJ software. Prior to re-probing for different targets, membranes were stripped by 217 incubation in near-boiling 0.1% SDS. Overall, let-7f-5p and let-7g-5p were the most abundant mature miRNAs, and were 237 upregulated 1.4-and 2.1-fold by 8 and 24 h SFN treatment, respectively, as illustrated by the 238 data presented in Figure 1 . Reads for miR-193b-3p were of moderate abundance, and 239 indicated 1.5-and 2.0-fold downregulation by 8 and 24 h SFN treatment, respectively, as 240 illustrated by the data presented in Figure 1 . Caco-2 by 8 but not 24 h SFN treatment, as illustrated by the data presented in Figure 3 [A]. 248
The Northern Blot experiment for miR-29b-3p indicated that it was downregulated in Caco-2 249 cells 1.5-and 1.7-fold by 8 and 24 h SFN treatment, respectively, as illustrated by the data 250 presented in Figure 3 let-7f-5p has adenine and uracil, while let-7g-5p has uracil and cytosine. This led to initial 255 speculation that the let-7f-5p and/or let-7g-5p probe(s) used for Northern Blotting might have 256 bound off-target to other let-7 miRNAs. In order to test the potential for such cross-hybridization, dot-blots of DNA oligonucleotides sense to the sequences of let-7a-5p, let-7b-258 5p, let-7c-5p, let-7d-5p, let-7e-5p, let-7f-5p, let-7g-5p and let-7i-5p were prepared, and then 259 probed using the let-7f-5p and let-7g-5p Northern Blot probes. 260
Densitometric dot analysis indicated that the let-7f-5p probe was largely specific to let-7f-5p, 261 albeit binding to let-7a-5p with affinity 6.3-fold lower than that with which it bound its target, 262 as illustrated by the data presented in Figure 4 , which also demonstrate that the let-7g-5p 263
Northern Blot probe was largely specific for its target, albeit binding to let-7i-5p with 5. containing a modified form of the CDC25A 3'-UTR portion, in which the predicted binding 285 site was mutated, had no effect. 286
The co-transfection of the mimic with the vector containing part of the HMGA2 3'-UTR, 287 with two predicted binding sites, repressed relative Firefly luciferase expression 1.6-fold, as 288 the data presented in Figure 6 [B] illustrate. However, co-transfection of the inhibitor with the 289 vector had no significant effect, but the co-transfection of inhibitor together with the mimic 290 and vector clearly abrogated the mimic's repressive effects. Neither the mimic nor inhibitor 291 affected relative Firefly luciferase expression when co-transfected with the mutated-binding-292 site form of the vector. 293
Co-transfection of the mimic with the vector containing part of the MYC 3'-UTR had no 294 effect on relative Firefly luciferase expression, but co-transfection of the inhibitor increased 295 such expression 1.4-fold, as illustrated by the data presented in Figure 6 [C]. Neither the 296 mimic nor inhibitor had any effect on relative Firefly luciferase expression when solely co-297 transfected with the mutant form of the vector, but when the mimic, inhibitor and vector were 298 all co-transfected at once, expression from the mutant vector unexpectedly increased 2.2-fold. 299
The co-transfection of neither the mimic nor inhibitor had any significant effect on relative 300
Firefly luciferase expression from the vector containing part of the KRAS 3'-UTR with one 301 predicted binding site, as illustrated by the data presented in Figure 6 The miRNA expression profiling data show that SFN (10µM) is able to upregulate the 307 expression of both let-7f-5p and let-7g-5p in the colonic adenocarcinoma Caco-2 cells, but 308 not in the non-cancerous colonic epithelial CCD-841 cells. The mechanism behind this 309 differential effect between the cell lines is unclear. One possibility is that SFN treatment 310 suppresses NF-κB in Caco-2 cells, thereby inhibiting lin28 and thus upregulating let-7 311 expression (25). The luciferase assay data demonstrate that let-7f-5p is indeed able to bind 312 directly to a locus in the CDC25A 3'-UTR that was computationally predicted as a let-7f-5p 313 binding site, and that said locus would play a role in the potential let-7f-5p-mediated 314 translational repression of CDC25A. They also confirm that the same miRNA is able to 315 directly bind one or more loci in the HMGA2 3'-UTR that were predicted as binding sites, 316 and that said loci could play a role in the potential let-7f-5p-mediated translational repression 317 of HMGA2. Finally, they suggest that the miRNA is able to directly bind to a 318 computationally-predicted binding site in the 3'-UTR of MYC, and that this site would play a 319 role in potential let-7f-5p-induced repression of MYC translation.
Overall, the data confirm that let-7f-5p and let-7g-5p were upregulated in Caco-2, but not in 321 CCD-841, by SFN (10µM) treatment, and that let-7f-5p can directly interact with loci in the 322 oncogenic CDC25A, HMGA2 and MYC 3'-UTRs. The let-7 family of miRNAs are widely 323 reported to have anti-proliferative, apoptotic and/or cell cycle arrest-inducing effects across a 324 number of cell types. Thus, the data presented here indicate that the translational repression 325 of CDC25A, HMGA2 and MYC is likely to contribute to the colorectal cancer-suppressive 326 effects of let-7 miRNAs, particularly let-7f-5p. They also demonstrate an apparent selectivity 327 of SFN-mediated let-7f-5p and let-7g-5p induction towards the cancerous Caco-2 cell line, 328 over the non-cancerous CCD-841 line. Such selectivity of let-7f-5p and/or let-7g-5p 329 induction may contribute to SFN's potential to favour cytotoxicity towards cancerous cells 330 over that towards healthy cells as reported in several contexts, and/or may serve to 331 counterbalance the Nrf2-mediated cytoprotective response to moderate-dose SFN that 332 inevitably occurs in tumour cells, whilst facilitating the cytoprotection of healthy cells. 333
Of additional interest is the observed SFN-mediated downregulation of miR-29b-3p in Caco-334 2 cells. The role of miR-29b-3p appears to be ambiguous, since both oncogenic (26) and 335 tumour-suppressive (27) functions are reported. MiR-29b-3p is computationally predicted by 336 miRanda to target the following tumour suppressor genes (TSGs): ADAMTS9, ARRDC3, 337 CASP7 , FEM1B, HBP1, HPGD, ING3, NAV3, PTEN, RhoBTB1, SEL1L, SLC5A8 , 338 SUV420H2, TET1, TET2 and UVRAG (24). Direct interactions between miR-29b-3p and the 339 3'-UTRs of colorectal cancer-suppressing TET1 and TET2 have been demonstrated by 340 luciferase assays already (28), (29), (30). Interestingly, a different ITC, phenethyl 341 isothiocyanate, was reported to inhibit the upregulation of miR-29b-3p in mouse lung tissue 342 mediated by environmental cigarette smoke (31). The ability of ITCs such as SFN and 343 phenethyl isothiocyanate to modulate miR-29b-3p levels might be at least partially 344 attributable to the induction of Nrf2, which itself has been reported to downregulate miR-29b-3p, via the binding at and consequent repression of transcription from, the miR-29b-1 346 genetic locus (32). Therefore, experiments to test the ability of miR-29b-3p to bind to these 347 predicted binding sites in the 3'-UTRs of these genes could lead to further insight into SFN's 348 potential to upregulate tumour suppressor gene expression in colorectal cancer. 349
In conclusion, SFN upregulates let-7f-5p and let-7g-5p in Caco-2 cells but not in Let-7f-5p is able to bind directly to loci in the 3'-UTRs of CDC25A, HMGA2 and MYC that 351 are computationally predicted as let-7f-5p binding sites, and may thus repress the translation 352 of these oncogenes. Normalized data are represented as triplicate means ± SEM (*p<0.05 according to two-tailed Student's T-test).
